Page last updated: 2024-10-24

chlorambucil and Tumour Lysis Syndrome

chlorambucil has been researched along with Tumour Lysis Syndrome in 2 studies

Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kosseifi, SG1
Vyas, B1
Vyas, H1
Krishnaswamy, G1
Smith, S1
Mahajan, A1
Nirmal, S1
English, MW1
Jenney, ME1
Lazda, ED1

Reviews

1 review available for chlorambucil and Tumour Lysis Syndrome

ArticleYear
Tumor lysis syndrome following chlorambucil therapy for chronic lymphocytic leukemia: case report and review of the literature.
    Tennessee medicine : journal of the Tennessee Medical Association, 2009, Volume: 102, Issue:10

    Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Glucocort

2009

Other Studies

1 other study available for chlorambucil and Tumour Lysis Syndrome

ArticleYear
Acute tumor lysis syndrome in Hodgkin disease.
    Medical and pediatric oncology, 2002, Volume: 39, Issue:1

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Chlorambucil; Hodgk

2002